{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:03:36Z","timestamp":1765713816102,"version":"3.33.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3440,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>The potential for disease progression in patients awaiting liver transplantation for hepatocellular carcinoma (HCC) has encouraged many centers to employ pre-transplant radiofrequency ablation or chemoembolization in an attempt to control tumor burden while patients are on the wait list. Despite general acceptance by the transplant community, few objective data demonstrate pre-transplant treatment efficacy or improved post-transplant outcomes in HCC patients listed with Model for End-Stage Liver Disease (MELD) exception points. To evaluate the utility of pre-transplant therapy in the current MELD era, we retrospectively compared 31 treated patients (T) with 33 untreated (U) controls. Study endpoints included patient and disease-free survival, tumor recurrence, explant tumor viability, and the ability of MRI to detect viable tumor after therapy. Both cohorts had similar demographic, radiographic, and pathologic characteristics, although untreated patients waited longer for transplantation [119 (U) vs. 54 (T) days after MELD assignment, (<jats:italic toggle=\"yes\">P<\/jats:italic> = .05); range: 1 day to 21 months]. Only 20% of treated tumors demonstrated complete ablation (necrosis) as defined by histologic examination of the entire lesion. Only 55% of lesions with histologic viable tumor were detected by MRI after pre-transplant therapy. After 36 months of follow-up, there was no difference between the treated and untreated groups in overall survival (84 vs. 91%), disease free survival (74% vs. 85%), cancer recurrence (23% vs. 12%), or mortality from cancer recurrence (57% vs. 25%) (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.1). In conclusion, viable tumor frequently persists after pre-transplant locoregional therapy, and neoadjuvant treatment does not appear to improve post-transplant outcomes in the current MELD era. <jats:bold>\n                                    Liver Transpl 12:665\u2013673, 2006.\n                                 <\/jats:bold>\n                                 <jats:bold>\u00a9 2006 AASLD.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.20636","type":"journal-article","created":{"date-parts":[[2006,2,15]],"date-time":"2006-02-15T23:47:08Z","timestamp":1140047228000},"page":"665-673","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":117,"title":["Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era"],"prefix":"10.1097","volume":"12","author":[{"given":"Paige M.","family":"Porrett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Peterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Sonnad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Soulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Markmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Shaked","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Furth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajender K.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Olthoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-26-20250124","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial.","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"R2-26-20250124","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"R3-26-20250124","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000658-200204000-00004","article-title":"Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeons perspective.","volume":"235","author":"Poon","year":"2002","journal-title":"Ann Surg"},{"key":"R4-26-20250124","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00000658-200009000-00010","article-title":"Radiofrequency ablation of hepatocellular carcinoma in 110 patients with cirrhosis.","volume":"232","author":"Curley","year":"2000","journal-title":"Ann Surg"},{"key":"R5-26-20250124","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/BF02725339","article-title":"Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.","volume":"7","author":"Wood","year":"2000","journal-title":"Ann Surg Oncol"},{"key":"R6-26-20250124","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.510300629","article-title":"Intentiontotreat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.","volume":"3","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"R7-26-20250124","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/jlts.2002.34923","article-title":"Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intentiontotreat principle and dropout from the waiting list.","volume":"8","author":"Yao","year":"2002","journal-title":"Liver Transpl"},{"key":"R8-26-20250124","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1053\/jlts.2003.50106","article-title":"Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.","volume":"9","author":"Graziadei","year":"2003","journal-title":"Liver Transpl"},{"key":"R9-26-20250124","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/archsurg.139.8.825","article-title":"The role of tumor ablation in bridging patients to liver transplantation.","volume":"139","author":"Johnson","year":"2004","journal-title":"Arch Surg"},{"key":"R10-26-20250124","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/jlts.2003.50147","article-title":"A followup analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implication for the current organ allocation policy.","volume":"9","author":"Yao","year":"2003","journal-title":"Liver Transpl"},{"key":"R11-26-20250124","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00000658-199712000-00006","article-title":"Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.","volume":"226","author":"Majno","year":"1997","journal-title":"Ann Surg"},{"key":"R12-26-20250124","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1600-6143.2005.00750.x","article-title":"The impact of preoperative locoregional therapy on outcome after liver transplantation for Hepatocellular carcinoma.","volume":"5","author":"Yao","year":"2005","journal-title":"Am J Transpl"},{"key":"R13-26-20250124","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1148\/radiology.214.3.r00mr02761","article-title":"Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions.","volume":"214","author":"Livraghi","year":"2000","journal-title":"Radiology"},{"key":"R14-26-20250124","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1148\/radiology.210.3.r99fe40655","article-title":"Small hepatocellular carcinoma: Treatment with radiofrequency ablation versus ethanol injection.","volume":"210","author":"Livraghi","year":"1999","journal-title":"Radiology"},{"key":"R15-26-20250124","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2214\/ajr.173.5.10541093","article-title":"Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging followup.","volume":"173","author":"Sironi","year":"1999","journal-title":"AJR Am J Roentgenol"},{"key":"R16-26-20250124","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1053\/jhep.2002.33635","article-title":"Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologyhistologic correlation during followup periods.","volume":"35","author":"Morimoto","year":"2002","journal-title":"Hepatology"},{"key":"R17-26-20250124","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1148\/radiology.192.3.8058934","article-title":"Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation.","volume":"192","author":"Spreafico","year":"1994","journal-title":"Radiology"},{"key":"R18-26-20250124","first-page":"1028","article-title":"Histologic evaluation and treatment outcome after sequential radiofrequency ablation and hepatic resection for primary and metastatic tumors.","volume":"68","author":"Hoffman","year":"2002","journal-title":"Am Surg"},{"key":"R19-26-20250124","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.sla.0000143301.56154.95","article-title":"Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study.","volume":"240","author":"Mazzaferro","year":"2004","journal-title":"Ann Surg"},{"key":"R20-26-20250124","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1053\/jlts.2002.36394","article-title":"Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation.","volume":"8","author":"Fontana","year":"2002","journal-title":"Liver Transpl"},{"key":"R21-26-20250124","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0168-8278(98)80123-2","article-title":"Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit?","volume":"29","author":"Oldhafer","year":"1998","journal-title":"J Hepatol"},{"key":"R22-26-20250124","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/000313480206800920","article-title":"Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy.","volume":"68","author":"Bloomston","year":"2002","journal-title":"Am Surg"},{"key":"R23-26-20250124","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1051-0443(07)61969-1","article-title":"Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology.","volume":"13","author":"Yamakado","year":"2002","journal-title":"J Vasc Interv Radiol"},{"key":"R24-26-20250124","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s002709900286","article-title":"Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: a retrospective study.","volume":"21","author":"Veltri","year":"1998","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R25-26-20250124","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0016-5085(85)90324-5","article-title":"Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.","volume":"89","author":"Sheu","year":"1985","journal-title":"Gastroenterology"},{"key":"R27-26-20250124","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/lt.20012","article-title":"Liver transplantation for hepatocellular carcinoma: the MELD impact.","volume":"10","author":"Sharma","year":"2004","journal-title":"Liver Transpl"},{"key":"R28-26-20250124","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1053\/j.gastro.2004.09.040","article-title":"Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy.","volume":"127","author":"Wiesner","year":"2004","journal-title":"Gastroenterology"},{"issue":"Suppl 11","key":"R29-26-20250124","first-page":"427","article-title":"HCC prioritization changes do not result in more advanced HCC at transplant.","volume":"5","author":"Mithoefer","year":"2005","journal-title":"Am J Transpl"},{"key":"R30-26-20250124","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/lt.20159","article-title":"Liver transplantation for hepatocellular carcinoma: lessons from the first year under the model of endstage liver disease (MELD) organ allocation policy.","volume":"10","author":"Yao","year":"2004","journal-title":"Liver Transpl"},{"key":"R31-26-20250124","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E","article-title":"Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.","volume":"7","author":"Edmondson","year":"1954","journal-title":"Cancer"},{"key":"R33-26-20250124","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/gut.50.1.123","article-title":"Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.","volume":"50","author":"Llovet","year":"2002","journal-title":"Gut"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.20636","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200604000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T16:14:38Z","timestamp":1737735278000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200604000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.20636","relation":{},"ISSN":["1527-6465"],"issn-type":[{"type":"print","value":"1527-6465"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}